HeartBeam Inc. (NASDAQ: BEAT), a medical technology company developing portable cardiac monitoring technology, will host a conference call on Thursday, Nov. 12, 2026, at 4:30 p.m. ET to discuss its financial results for the third quarter ended Sept. 30, 2026, according to a company announcement. The quarterly press release will be issued before the call.
The call is notable less for the routine quarterly numbers than for the clinical and strategic updates management plans to provide. HeartBeam said executives will discuss recent achievements, including results from the ALIGN-ACS pilot study, and upcoming milestones for its Heart Attack Detection program. For investors and clinicians tracking the company, those disclosures may carry more weight than the financial statements themselves, given that they speak to the progress of the company's core technology.
Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic, Ph.D., and Chief Financial Officer Timothy Cruickshank will host the call, followed by a question-and-answer session. Participants can dial 1-877-704-4453 domestically or 1-201-389-0920 internationally using conference code 13763268. A webcast and accompanying presentation will be available, and a telephone replay will be accessible approximately three hours after the call through Nov. 26, 2026. The full press release is available at https://ibn.fm/QEwx4.
HeartBeam is developing what it describes as the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. The platform is designed for portable use wherever a patient is, with the goal of delivering actionable heart intelligence so physicians can identify cardiac trends and acute conditions and direct patients to appropriate care outside a medical facility. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software was cleared in December 2025. HeartBeam holds more than 20 issued patents related to technology enablement. Details on the cleared indications for use are available at https://www.heartbeam.com/indications.
The significance for the broader cardiac care market lies in the company's effort to move ECG collection beyond the clinic. If HeartBeam's platform performs as intended, it could change how quickly acute cardiac events such as heart attacks are detected and how patients are triaged, a prospect that matters to hospitals, emergency responders, insurers and patients alike. The ALIGN-ACS pilot study results and the Heart Attack Detection program milestones discussed on the call will therefore be watched as indicators of how close that vision is to clinical and commercial reality.
HeartBeam is followed through the HeartBeam (NASDAQ: BEAT) relationship page maintained by MissionIR, a communications platform within the Dynamic Brand Portfolio at IBN. The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT.
